Improving CAR-T cell therapy for solid tumors using targeted radiation treatment
Official title: Enhancing CAR-T cell therapy through theranostic targeted radionuclide therapy
Funded at Methodist Hospital Research Institute · NIH-10946201 · Data updated 2026-11-12
This study is exploring a new way to make CAR-T cell therapy even better for treating solid tumors by combining it with a special type of radiation, hoping to help patients fight their cancer more effectively.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | June 1, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $415,260 |
| NIH project number | 1R21CA292224-01 |
| Project ID | NIH-10946201 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with solid tumors who have not responded to conventional therapies or have refractory cancer.
✕Less likely to help
Patients with blood cancers or those who are not eligible for CAR-T cell therapy may not benefit from this research.
What this research studies
This research focuses on enhancing CAR-T cell therapy, a promising cancer treatment, by integrating it with targeted radionuclide therapy. The approach aims to improve the effectiveness of CAR-T cells in treating solid tumors, which have been challenging to target with current therapies. By using a specific type of radiation therapy delivered through CAR-T cells, the study seeks to boost the immune response against tumors and improve patient outcomes. Patients may benefit from this innovative combination therapy that aims to overcome existing limitations in cancer treatment.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment options for patients with solid tumors, potentially leading to better outcomes and increased survival rates.
How similar studies have gone: Previous studies have shown promise in combining CAR-T cell therapy with other treatment modalities, suggesting potential for success with this novel approach.
Where this research is happening
-
Methodist Hospital Research Institute
Houston, United States Active
Researchers
- Principal investigator: Yang, Yanping — Methodist Hospital Research Institute
- Study coordinator: Yang, Yanping
Related research
Other NIH-funded projects on the same topics.
-
SynthNode: A new, easier way to make CAR T cells for better cancer treatment
A new implantable device called SynthNode could simplify and lower the cost of CAR T cell therapy, helping patients with lymphoma, myeloma, and potentially solid tumors or lupus.
-
Intraperitoneal CAR T cells for peritoneal mesothelioma
A new approach uses CAR T cells delivered directly into the abdominal cavity to target mesothelioma, aiming to help people whose disease is confined to the abdomen.
-
Photobiomodulation to Boost CAR-T Cell Therapy for B-Cell Cancers
A patient-facing overview of using light-based therapy to improve CAR-T cell treatment for B-cell cancers, aiming for better effectiveness and lower costs.
-
Targeting death receptors to boost MET-CAR T cells for glioblastoma
Aims to make MET-CAR T cells work better against glioblastoma by using radiation to trigger death receptors on tumor cells.
-
CTO1681: reducing dangerous immune reactions in patients getting CAR T-cell therapy
A new oral drug (CTO1681) aims to prevent and lessen cytokine release syndrome in patients with blood cancers treated with CAR T-cell therapy.
-
CD2-targeted CAR-T therapy for T-cell lymphoma in a multi-center program
A patient-focused overview of a research grant that aims to improve CAR-T cell therapy for T-cell lymphoma by exploring CD2 as a new target and enhancing allogeneic CAR-T safety features.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.